X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Funding will support development of SBP-101 is a proprietary polyamine analogue designed to induce polyamine metabolic inhibition (PMI) by exploiting an observed high affinity of the compound for the exocrine pancreas and pancreatic ductal adenocarcinoma.
Lead Product(s): Diethyl dihydroxyhomospermine,Enzalutamide,Gemcitabine
Therapeutic Area: Oncology Product Name: SBP-101
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Craig-Hallum Capital Group
Deal Size: $10.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering September 01, 2020
Details:
The company's lead candidate, SBP-101, is a small molecule polyamine metabolic inhibitor delivered subcutaneously for the treatment of pancreatic cancer and solid tumors.
Lead Product(s): Diethyl dihydroxyhomospermine,Enzalutamide,Gemcitabine
Therapeutic Area: Oncology Product Name: SBP-101
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $12.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering July 02, 2020
Details:
The company has received Fast Track Designation from the U.S. FDA for its lead product, SBP-101, being developed for firstline treatment of patients with metastatic pancreatic ductal adenocarcinoma (PDA) when administered in combination with gemcitabine and nab-paclitaxel.
Lead Product(s): Diethyl dihydroxyhomospermine,Enzalutamide,Gemcitabine
Therapeutic Area: Oncology Product Name: SBP-101
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 01, 2020
Details:
The COVID-19 pandemic has affected the conduct of clinical trials at US and Australian sites. Some cancer centers have redeployed resources to prioritize COVID-19 patient care activities.
Lead Product(s): Diethyl dihydroxyhomospermine,Paclitaxel,Gemcitabine
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 03, 2020
Details:
SBP-101 was well tolerated in combination with gemcitabine and nab-paclitaxel.
Lead Product(s): Diethyl dihydroxyhomospermine,Paclitaxel,Gemcitabine
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 24, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
